Recent Updates
Recently added Catalysts
ANRO Positive Sentiment

Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alto Neuroscience reported its financial results for Q3 2026, showcasing advancements in its clinical programs. The company emphasized its focus on developing precision medicines for neuropsychiatric disorders. Additionally, Alto highlighted improvements in its financial standing during this period.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alto reported progress in its clinical programs.
  • The company strengthened its financial position.
  • Continued development of novel precision medicines.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+393%
120-day peak, hindsight
Typical move
10.5%
average across 2 past catalysts
Cash runway
~34 mo
Low dilution risk
Lead asset
ALTO-100
Phase 2 · Bipolar Disorder I or II With a Major Depressive Episode

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahe

Frequently Asked Questions

What were Alto Neuroscience's Q3 2026 financial results?

Alto Neuroscience reported financial results for Q3 2026, highlighting progress in its pipeline.

What is Alto Neuroscience focused on?

Alto focuses on developing precision medicines for neuropsychiatric disorders.

How did Alto improve its financial position?

The company strengthened its financial position during the third quarter.

What are the recent highlights for Alto Neuroscience?

Alto highlighted advancements in its clinical programs and financial improvements.

ShareAdd on Google
Tags: ANRO Alto Neuroscience financial results clinical programs neuropsychiatric disorders
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$244M liquidity · $7M/mo burn
~34 mo
Low dilution risk
Lead asset
ALTO-100Phase 2
Bipolar Disorder I or II With a Major Depressive Episode →

Catalyst track record

+393%
best trade around ANRO's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ANRO.

See every catalyst's timing & PoA →